共 107 条
[11]
Younes A(2008)Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 906-1825
[12]
Wilson FP(2005)Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia Pharmacotherapy. 25 1820-625
[13]
Berns JS(2004)Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration J Cancer Res Clin Oncol 130 623-2382
[14]
Coiffier B(2008)Bortezomib-associated tumor lysis syndrome in multiple myeloma Leuk Lymphoma 49 2380-235
[15]
Altman A(2006)Bortezomib-induced tumor lysis syndrome in multiple myeloma Clin Lymphoma Myeloma 7 233-631
[16]
Pui CH(2008)Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up Ann Hematol 87 623-6662
[17]
Younes A(2016)High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib Anticancer Res 36 6655-441
[18]
Cairo MS(2014)Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients Jpn J Clin Oncol 44 435-458
[19]
Williams SM(2013)Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 452-150
[20]
Killeen AA(2013)Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the Evaluation and management of chronic kidney disease Kidney Inter Suppl 3 1-1557